---
title: "Faeth Therapeutics grants performance options to Anand Parikh, Christopher Gerry and Josiah Craver"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293670210.md"
description: "Faeth Therapeutics granted one-time performance-based stock options to CEO Anand Parikh, General Counsel Christopher Gerry, and SVP Finance Josiah Craver under its 2026 Equity Incentive Plan. The grants, effective July 21, 2026, vest upon meeting a $70 stock-price hurdle and one-year service. Options were approved by the Board based on Compensation Committee recommendations."
datetime: "2026-07-23T21:23:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293670210.md)
  - [en](https://longbridge.com/en/news/293670210.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293670210.md)
---

# Faeth Therapeutics grants performance options to Anand Parikh, Christopher Gerry and Josiah Craver

**Faeth Therapeutics awarded one-time performance-based stock options to CEO Anand Parikh, General Counsel Christopher Gerry and SVP Finance Josiah Craver under its 2026 Equity Incentive Plan.**

**Individual**

Anand Parikh

Christopher Gerry

Josiah Craver

**Role**

Chief Executive Officer

General Counsel and Secretary

Senior Vice President, Finance

**Type of Change**

Awarded performance-based stock option

Awarded performance-based stock option

Awarded performance-based stock option

**Effective Date**

July 21, 2026

July 21, 2026

July 21, 2026

**Reason**

One-time supplemental grant approved by Board upon Compensation Committee recommendation

One-time supplemental grant approved by Board upon Compensation Committee recommendation

One-time supplemental grant approved by Board upon Compensation Committee recommendation

**Replacement Info**

Not disclosed

Not disclosed

Not disclosed

**Background Details**

Granted 398,018 Performance Options; exercise price = Nasdaq closing price on grant; vesting upon meeting $70 stock-price hurdle and one-year service

Granted 84,766 Performance Options; exercise price = Nasdaq closing price on grant; vesting upon meeting $70 stock-price hurdle and one-year service; Board determined in June 2026 he is not an "executive officer" under Rule 3b-7

Granted 30,824 Performance Options; exercise price = Nasdaq closing price on grant; vesting upon meeting $70 stock-price hurdle and one-year service; Board determined in June 2026 he is not an "executive officer" under Rule 3b-7

**Board/Committee Role Changes**

Not disclosed

Not disclosed

Not disclosed

Original SEC Filing: Faeth Therapeutics, Inc. \[ FTH \] - 8-K - Jul. 23, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [FTH.US](https://longbridge.com/en/quote/FTH.US.md)

## Related News & Research

- [Faeth Therapeutics files initial beneficial ownership statement for Khosla Ventures VI, L.P](https://longbridge.com/en/news/294108113.md)
- [IWM Long Strangle Benefits from Large Stock Price Moves](https://longbridge.com/en/news/293767641.md)
- [Option Volatility And Earnings Report For July 27-31](https://longbridge.com/en/news/293920673.md)
- [Despite Challenges, AST SpaceMobile Stock Could Make a Compelling Options Trade for Contrarians Here](https://longbridge.com/en/news/293947348.md)
- [Trident Resources grants 1,525,000 stock options at $3.75 per share](https://longbridge.com/en/news/293797358.md)